Tharimmune, Inc. (NASDAQ:THAR) Short Interest Down 27.0% in August

Tharimmune, Inc. (NASDAQ:THAR) was the target of a significant drop in short interest during the month of August. As of August 15th, there was short interest totalling 13,800 shares, a drop of 27.0% from the July 31st total of 18,900 shares. Based on an average trading volume of 53,200 shares, the short-interest ratio is presently 0.3 days. Approximately 1.2% of the shares of the company are sold short.

Tharimmune Trading Down 2.8 %

Tharimmune stock traded down $0.08 during midday trading on Friday, hitting $2.72. 6,431 shares of the company’s stock were exchanged, compared to its average volume of 38,739. Tharimmune has a 12-month low of $2.54 and a 12-month high of $142.50. The firm’s 50 day simple moving average is $3.23 and its 200 day simple moving average is $4.69.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).